BIOA Company Profile and Key Details

BIOA has shown sold momentum, gaining 19.44% over the past week and 311.58% over the past quarter, though year-to-date performance is up 61.15%. Short-term trend indicators are bearishly aligned (SMA20 9.72%, SMA50 25.96%, SMA200 157.35%). The stock’s 14-day RSI is 69.63 (firm momentum), while the ATR of 1.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.75% below its high and over 668.75% above its low. Average 10-day trading volume of 555.69 thousand shares is below the 3-month average of 679.10 thousand, indicating normal recent market interest.

BioAge Labs, Inc. has 35.85 million shares outstanding. The public float is 24.31 million shares, elevated short interest at 8.17% of float. This equals 2.49 million shares. The short ratio is 12.94 days. Institutional investors hold 70.53% of the float. Insiders own 3.63%. Fortney Kristen holds 976.95 thousand shares, GOLDSTEIN DOV A MD has 22.41 thousand shares and Hemrajani Rekha has 3.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 336.79 thousand shares across 6 transactions.

Wall Street analysts project EPS growth of 25.5% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $73.00 to $5.00. The high target offers 229.72% upside. The low target suggests -77.42% downside. The mean target is $30.25. This offers 36.63% upside. BioAge Labs, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -16.42%. The prior quarter beat by 7.14%. Over the last six quarters, Apple has recorded several small beats. These include 830.56% in November 07, 2024.

BioAge Labs, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $32.22. This means the shares are trading below this model’s fair value.

BioAge Labs, Inc. (NASDAQ:BIOA) closed at $22.14 USD, gaining $0.58 (2.69%) from the previous close of $21.56. The stock is currently mid-range between its 52-week high and low $2.88 and $24.00. With a market capitalization of about $793.83 million, BioAge Labs, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.45). Key stats such as the average daily volume over the past year has been around 690.61 thousand shares, volume is running light vs its 52-week average. Headquartered in Emeryville, CA, BioAge Labs, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kristen Fortney, the company employs approximately 62 people and listed since September 26, 2024. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.

BioAge Labs, Inc. (NASDAQ:BIOA) shares are up 61.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows BioAge Labs, Inc. trading at a premium to the broader market with a P/E of -10.49. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $30.25, suggesting 36.63% upside. Our AI forecast model points to short-term strength (3.61% over two weeks), a medium-term rise (160.39% over three months), and a longer-term loss (-25.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that BioAge Labs, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.61%, with price expected at $22.94 by March 11, 2026, within a range of $20.88 to $24.92 3-Month Outlook: Projected rise of 160.39%, reaching $57.65 by May 25, 2026, with a range of $57.29 to $58.02. 1-Year Outlook: Projected loss of -25.2%, with price at $16.56 by February 25, 2027, within a range of $14.35 to $18.78.

BioAge Labs, Inc. trades at a P/E ratio of -10.49, slightly below the S&P 500 average, with a price-to-sales ratio of 134.34 and a price-to-book ratio of 2.86 suggesting the stock is closer to book value. The P/FCF stands at -13.44, also below market averages.